93 related articles for article (PubMed ID: 30462431)
1. [The first results of assessment of clinical efficacy of melatonin and metformin in patients with disseminated skin melanoma receiving dacarbazine as first-line systemic therapy].
Novik AV; Protsenko SA; Baldueva IA; Berstein LM; Anisimov VN; Semenova AI; Latipova DK; Tkachenko EV; Semiglazova TY
Vopr Onkol; 2016; 62(2):324-9. PubMed ID: 30462431
[TBL] [Abstract][Full Text] [Related]
2. Melatonin and Metformin Failed to Modify the Effect of Dacarbazine in Melanoma.
Novik AV; Protsenko SA; Baldueva IA; Berstein LM; Anisimov VN; Zhuk IN; Semenova AI; Latipova DK; Tkachenko EV; Semiglazova TY
Oncologist; 2021 May; 26(5):364-e734. PubMed ID: 33749049
[TBL] [Abstract][Full Text] [Related]
3. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.
Kefford RF; Clingan PR; Brady B; Ballmer A; Morganti A; Hersey P
Mol Cancer; 2010 Mar; 9():69. PubMed ID: 20350333
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
Rusthoven JJ; Quirt IC; Iscoe NA; McCulloch PB; James KW; Lohmann RC; Jensen J; Burdette-Radoux S; Bodurtha AJ; Silver HK; Verma S; Armitage GR; Zee B; Bennett K
J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240
[TBL] [Abstract][Full Text] [Related]
6. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
Ferrucci PF; Minchella I; Mosconi M; Gandini S; Verrecchia F; Cocorocchio E; Passoni C; Pari C; Testori A; Coco P; Munzone E
Melanoma Res; 2015 Jun; 25(3):239-45. PubMed ID: 25746039
[TBL] [Abstract][Full Text] [Related]
7. [Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma].
Gershanovich ML; Akimov MA
Vopr Onkol; 2004; 50(2):179-83. PubMed ID: 15176220
[TBL] [Abstract][Full Text] [Related]
8. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
Bajetta E; Di Leo A; Zampino MG; Sertoli MR; Comella G; Barduagni M; Giannotti B; Queirolo P; Tribbia G; Bernengo MG
J Clin Oncol; 1994 Apr; 12(4):806-11. PubMed ID: 8151323
[TBL] [Abstract][Full Text] [Related]
9. Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma.
Nieboer P; Mulder NH; Van Der Graaf WT; Willemse PH; Hospers GA
Anticancer Res; 2001; 21(4B):3115-6. PubMed ID: 11712820
[TBL] [Abstract][Full Text] [Related]
10. Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures: a single-center study.
Jelić S; Babović N; Stamatović L; Kreacić M; Matković S; Popov I
Med Oncol; 2001; 18(3):189-95. PubMed ID: 11917943
[TBL] [Abstract][Full Text] [Related]
11. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
13. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
14. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma.
Luikart SD; Kennealey GT; Kirkwood JM
J Clin Oncol; 1984 Mar; 2(3):164-8. PubMed ID: 6199481
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.
Margolin KA; Liu PY; Flaherty LE; Sosman JA; Walker MJ; Smith JW; Fletcher WS; Weiss GR; Unger JM; Sondak VK
J Clin Oncol; 1998 Feb; 16(2):664-9. PubMed ID: 9469356
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
Ranson M; Hersey P; Thompson D; Beith J; McArthur GA; Haydon A; Davis ID; Kefford RF; Mortimer P; Harris PA; Baka S; Seebaran A; Sabharwal A; Watson AJ; Margison GP; Middleton MR
J Clin Oncol; 2007 Jun; 25(18):2540-5. PubMed ID: 17577032
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
Papadopoulos NE; Bedikian A; Ring S; Kim KB; Hwu WJ; Gerber DL; Homsi J; Hwu P
Am J Clin Oncol; 2009 Oct; 32(5):509-14. PubMed ID: 19506454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]